ethyl 5-amino-4-methylpyridine-2-carboxylate | 1073435-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ethyl 5-amino-4-methylpyridine-2-carboxylate
• CAS: 1073435-81-0
• 化学式: C₉H₁₂N₂O₂
• 分子量: 180.206
• InChiKey: OBZUDIQXKIOIMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-amino-4-methylpyridine-2-carboxylate 在 sodium periodate 、 碘 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 144.0h， 生成 ethyl 5-amino-6-iodo-4-methylpyridine-2-carboxylate
  参考文献：
  名称：

  NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

  摘要：

  公开号：

  EP2143724B1
• 作为产物：
  描述：

  ethyl 4-methyl-5-nitropyridine-2-carboxylate 在 palladium-carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to give the title compound (2.74 g)的产率得到ethyl 5-amino-4-methylpyridine-2-carboxylate
  参考文献：
  名称：

  NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

  摘要：

  [目的]本发明提供一种化合物，可用作预防或治疗性激素依赖性疾病等药物。 [解决方案]本发明提供一种氮杂环融合衍生物，其具有GnRH拮抗活性，包括前药、盐、含有该化合物的药物组成物、药物用途等。该化合物的通式(I)如下：在式(I)中，环A和环B独立地是芳基或杂芳基；RA和RB独立地是卤素、氰基、烷基、烷基磺酰、—OW1、—SW1、—COW2、—NW3W4、—SO2NW3W4、芳基等；RC是氢或烷基；E是氧原子等；U是单键或烷基；X是Y、—CO—Y、—SO2—Y、—S-(烷基)-Y、—O-(烷基)-Y、—SO2-(烷基)-Y等；Y是Z或氨基等；Z是环烷基、杂环烷基、芳基、杂芳基等。

  公开号：

  US20100112090A1

文献信息

• Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08217069B2

  公开（公告）日：2012-07-10

  [Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, —OW1, —SW1, —COW2, —NW3W4, —SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, —CO—Y, —SO2—Y, —S-(alkylene)-Y, —O-(alkylene)-Y, —SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

  [目的] 本发明提供一种化合物，可用作预防或治疗性激素依赖性疾病或类似疾病的药物。 [解决方案] 本发明提供一种氮杂环融合衍生物，其表示为以下通式（I），具有GnRH拮抗活性，包括前药、盐、含有该化合物的制药组合物、药用用途等。 在式（I）中，环A和环B分别是芳基或杂芳基；RA和RB分别是卤素、氰基、烷基、烷基磺酰基、—OW1、—SW1、—COW2、—NW3W4、—SO2NW3W4、芳基等；RC是氢或烷基；E是氧原子等；U是单键或烷基；X是Y、—CO—Y、—SO2—Y、—S-（烷基）-Y、—O-（烷基）-Y、—SO2-（烷基）-Y等；Y是Z或氨基等；Z是环烷基、杂环烷基、芳基、杂芳基等。
• Thiazolidinone compounds and use thereof
  申请人：National Health Research Institutes

  公开号：US10544113B2

  公开（公告）日：2020-01-28

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有用于治疗阿片受体相关疾病的式 (I) 化合物的药物组合物。还公开了一种使用此类化合物治疗阿片受体相关疾病的方法。进一步公开了两组式(I)的噻唑烷酮化合物：(i)对映体过量大于 90%的化合物和(ii)各自被氘取代的化合物。
• US8217069B2
  申请人：——

  公开号：US8217069B2

  公开（公告）日：2012-07-10
• [EN] THIAZOLIDINONE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE THIAZOLIDINONE ET LEUR UTILISATION
  申请人：SHIH CHUAN

  公开号：WO2017155910A1

  公开（公告）日：2017-09-14

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.
• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。